Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6841 to 6855 of 7691 results

  1. Blepharitis: antimicrobial prescribing

    Discontinued [GID-NG10168]

    Antimicrobial prescribing guideline
    Discontinued

  2. Interferon beta-1b, interferon beta-1a and glatiramer acetate for the treatment of single demyelinating event with clinically isolated syndrome [ID109]

    Discontinued [GID-TAG415]

    Technology appraisal guidance
    Discontinued

  3. Vandetanib for treating metastatic, differentiated thyroid cancer refractory to or unsuitable for radioiodine therapy [ID907]

    Discontinued [GID-TA11259]

    Technology appraisal guidance
    Discontinued

  4. Bavituximab for treating non-squamous non-small-cell lung cancer after platinum-based chemotherapy [ID975]

    Discontinued [GID-TA11260]

    Technology appraisal guidance
    Discontinued

  5. Triptorelin for the adjuvant treatment of early breast cancer in premenopausal women [ID976]

    Discontinued [GID-TA11261]

    Technology appraisal guidance
    Discontinued

  6. Ataluren for treating cystic fibrosis in people with a CFTR gene nonsense mutation [ID955]

    Discontinued [GID-TA11262]

    Technology appraisal guidance
    Discontinued

  7. ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]

    Discontinued [GID-TA10259]

    Technology appraisal guidance
    Discontinued

  8. Nilotinib for the first line treatment of chronic myeloid leukaemia [ID79]

    Discontinued [GID-TAG408]

    Technology appraisal guidance
    Discontinued

  9. Psoriatic arthritis (moderate to severe) - leflunomide [ID391]

    Discontinued [GID-TAG385]

    Technology appraisal guidance
    Discontinued

  10. Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]

    In development [GID-TA10575] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Diabetic retinopathy - ruboxistaurin [ID382]

    In development [GID-TAG386] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Atrial fibrillation - idraparinux sodium [ID375]

    Discontinued [GID-TAG383]

    Technology appraisal guidance
    Discontinued

  13. Cardiovascular events (prevention, high risk) - anacetrapib [ID1164]

    Discontinued [GID-TA11176]

    Technology appraisal guidance
    Discontinued

  14. Osteoarthritis - diacerein [ID332]

    Discontinued [GID-TAG250]

    Technology appraisal guidance
    Discontinued

  15. Nivolumab monotherapy for non-small-cell lung cancer [ID1088]

    Discontinued [GID-TA10148]

    Technology appraisal guidance
    Discontinued